Detalhe da pesquisa
1.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
2.
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Future Oncol
; 17(10): 1165-1184, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583206
3.
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
Curr Ther Res Clin Exp
; 95: 100640, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34484473
4.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28885881
5.
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Lancet Oncol
; 20(12): 1670-1680, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31601496
6.
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.
Oncologist
; 24(12): 1510-e1265, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350329
7.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol
; 19(4): 521-536, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545095
8.
Nelfinavir inhibits maturation and export of herpes simplex virus 1.
J Virol
; 88(10): 5455-61, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574416
9.
Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Int J Oncol
; 63(5)2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37800623
10.
A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice.
Carcinogenesis
; 32(8): 1279-84, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21625009
11.
Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors.
In Vivo
; 35(1): 141-145, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33402459
12.
Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Anticancer Res
; 41(1): 91-99, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33419802
13.
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Clin Lung Cancer
; 22(6): 549-561, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294595
14.
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Lung Cancer
; 151: 30-38, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285469
15.
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Cancer Discov
; 11(11): 2828-2845, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34230008
16.
Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
J Exp Med
; 198(9): 1337-47, 2003 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-14581607
17.
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Clin Pharmacol Ther
; 108(6): 1274-1288, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564368
18.
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Cancer Discov
; 10(12): 1842-1853, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816849
19.
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
Lung Cancer
; 147: 137-142, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702570
20.
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol
; 15(2): 288-293, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31622733